Peptides for hair growth: what the studies show
Reviewed 17 sourcesPublished by PepVault
Every peptide tried for hair growth in one graded table: the trials in people, the mouse-only peptides, who paid for the studies, and how minoxidil compares.

- Last reviewed
- Sources
- 17
- Questions
- 7
- Compounds
- 3
The short answer
No peptide is approved for hair loss, and none has trials near the size of minoxidil's or finasteride's. The best human data are small cosmetic trials: a pentapeptide lotion raised the share of thick hairs in 22 men, and a tetrapeptide blend did as well as 3% minoxidil in 32 people. Thymosin beta-4 and PTD-DBM have only rodent data.
Evidence: Small cosmetic trials of peptide products in people (18 to 45 per trial, most of them blends), one eyebrow trial of GHK-Cu, and rodent and cell studies for thymosin beta-4, PTD-DBM and AHK-Cu; no peptide is approved for hair loss.

Which peptides have been tested for hair growth?
Nine peptides or peptide products have a hair study worth reading, and six of them have been tested on people, five in controlled trials. Each hair grows from a follicle, the small pocket in the skin that builds the hair shaft. A follicle cycles between anagen, the growing phase, and telogen, the resting phase. In pattern hair loss the follicles shrink and anagen shortens, so thick hairs come back as vellus hairs, the fine, short, pale kind. Every study below measures one of those things: how many hairs, how thick, or how many follicles are growing.
| Peptide | How applied | Best study | In whom | What was measured | Result | Evidence level |
|---|---|---|---|---|---|---|
| Gly-Pro-Ile-Gly-Ser (a pentapeptide) | Scalp lotion | Iwabuchi 20162 | 22 Japanese men with pattern hair loss, 4 months, vs the same lotion without it | Share of thick hairs (60 µm or more) | Rose more than on placebo (p = 0.006); fewer vellus hairs; better blinded photo grades | One small randomized trial |
| Acetyl tetrapeptide-3, with biochanin A and ginseng | Scalp lotion, twice daily | Lueangarun 20203 | 32 men and women, 24 weeks, vs 3% minoxidil | Terminal hair count | +8.3% vs +8.7% on minoxidil; no significant difference | One small randomized trial |
| Biotinoyl tripeptide-1, with apigenin and oleanolic acid (sold as Procapil) | 3% scalp lotion, twice daily | The maker's pilot, reported in Bikash 20254 | 35 men, 4 months, vs placebo | Ratio of growing to resting hairs | Improved in 67% of the 18 men on the lotion | Manufacturer's pilot, not peer reviewed |
| GHK without copper, bound to 5-aminolevulinic acid | Scalp solution, once daily | Lee 20165 | 45 men with pattern hair loss, 6 months, vs placebo | Hair count, thickness, length | Count rose 52.6 and 71.5 on two strengths vs 9.6 on placebo (significant vs placebo for the lower strength); thickness and length unchanged | One small randomized trial |
| GHK-Cu | 2% serum, twice daily | Bo 20266 | 18 adults, one eyebrow treated and the other on placebo, 12 weeks | Hair count and diameter | Count rose on the treated brow and not on the placebo brow; diameter also improved | One small trial, eyebrows only |
| AHK-Cu (a related copper peptide) | Added to the culture dish | Pyo 20077 | Human hair follicles and papilla cells in a dish | Follicle length, cell growth | Follicles grew longer; papilla cells multiplied | Cells only |
| Thymosin beta-4 | Given to animals | Philp 20048 | Rats and mice | Hair growth | Faster hair growth | Animal only |
| PTD-DBM | Given to animals | Lee 201710 | Mice | Regrowth and new follicles after a wound | Faster regrowth; more new follicles | Animal only |
| Growth-factor mix with copper tripeptide-1 and thymosin beta-4 | Scalp injections every 3 weeks, 8 sessions | Kapoor 201811 | 1,000 patients, no control group | Pull test, hair counts | Less shedding in 83%; peptides' share unknown | Uncontrolled |
| For scale: minoxidil 5% (not a peptide) | Scalp solution, twice daily | Olsen 200212 | 393 men, 48 weeks, vs 2% and placebo | Non-vellus hair count | Beat 2% and placebo; 45% more regrowth than 2% | Large randomized trials; approved |
| For scale: finasteride 1 mg (not a peptide) | Tablet, daily | Kaufman 199813 | 1,553 men, 1 year, vs placebo | Hairs in a 5.1 cm² circle (start: 876) | 107 more hairs than placebo at 1 year | Large randomized trials; approved |


Species note: the AHK-Cu result is from human tissue in a dish, and the thymosin beta-4 and PTD-DBM results are from rats and mice. They show a peptide acting on follicles, not a product regrowing a person's hair.

Which peptide has the best evidence in people?
The pentapeptide and the tetrapeptide blend, by a short head. A 2026 systematic review searched three databases in November 2025, found 981 records and kept 14 clinical trials of peptide products for hair loss in people1. It gave a grade of recommendation B to formulas with acetyl tetrapeptide-3, biotinoyl tripeptide-1, GHK and the pentapeptide Gly-Pro-Ile-Gly-Ser, and grade C to the injectable QR678 products1. No peptide reached grade A.
The pentapeptide trial is the cleanest test of one peptide on its own: the same lotion with and without it, randomized and double-blind, and the thick-hair share moved while the fine-hair share fell2. The tetrapeptide trial is the one head-to-head test in a PubMed-indexed journal, and it matched 3% minoxidil, a strength below the 5% that the large trials favour312. A 106-man trial of a blend holding both peptides plus Redensyl scored better than 5% minoxidil on rater and photo scores, in a journal outside PubMed4. Both are small, and the tetrapeptide was one of three actives in the bottle.
Who paid for the cosmetic peptide trials?
Often, the company that sells the ingredient. The pentapeptide trial was led by researchers at Shiseido's innovation centre2. The first data on Procapil and on Capixyl, the acetyl tetrapeptide-3 complex, come from their makers' own technical files, Sederma's and Lucas Meyer Cosmetics', not from journals. Capixyl's file reports 30 men over 4 months, with the ratio of growing to resting hairs up 46% on the lotion and down 33% on placebo4.
The independent work is thinner but exists. The tetrapeptide-versus-minoxidil trial reported no funding3. The GHK trial was paid for by a regional Korean small-business agency, with thanks to a medical supply company5. A 2025 review of these cosmetic actives found most of their studies small, rarely compared with standard treatment and often carrying conflicts of interest4. PTD-DBM comes from a Yonsei University lab whose senior author is chief executive of CK Regeon, the company licensed to develop it1017.
What does GHK-Cu do for hair?
GHK-Cu, a three-amino-acid peptide holding a copper ion, is the peptide most often sold for hair, yet its one controlled human hair trial is on eyebrows. In 18 adults, the brow treated twice daily with a 2% serum gained hairs over 12 weeks while the placebo brow did not change, and its hairs grew thicker, with no serious side effects6. The one randomized scalp trial used GHK without its copper, bound to another active, and it raised hair counts but not thickness5. As of November 2026, no trial has tested GHK-Cu on its own on scalp hair loss.
GHK-Cu has two guides of its own. GHK-Cu for skin and hair covers the wrinkle, wound and eyebrow trials and what injecting it has never tested. GHK-Cu vs minoxidil for hair sets the two side by side, from the labels to the one mouse study that compared them.
Do thymosin beta-4 and PTD-DBM grow hair?
In rodents, yes; in people, nobody has measured it. Thymosin beta-4 is a 43-amino-acid protein your cells use to move and repair; TB-500, a synthetic copy of its seven-amino-acid actin-binding stretch (residues 17 to 23), has no hair study of its own16. In normal rats and mice it sped hair growth, and in a dish it made rat whisker-follicle cells, close kin of the stem cells in the follicle's bulge (the reservoir that restocks a follicle each cycle), migrate and mature faster8. Mice bred to overproduce it in their skin regrew hair faster after hair removal, and mice bred without it regrew slower9.
PTD-DBM is a lab-built peptide that releases a brake on the Wnt pathway, a signal follicles need to start a new growth phase. The brake, a protein called CXXC5, was raised in shrunken follicles from human balding scalps, and in mice the peptide sped regrowth and the forming of new follicles in healing wounds10. On November 20, 2026, ClinicalTrials.gov listed no trial of PTD-DBM, or of thymosin beta-4 for hair loss.
How do minoxidil and finasteride compare?
They are the bar every peptide is measured against, and both are approved for pattern hair loss as of November 2026. Minoxidil 5% is sold over the counter for men; its label covers the top of the scalp, not a receding hairline, says results may show at 2 months or take 4, and says hair loss begins again if use stops14. Finasteride 1 mg is a prescription tablet for men only; its label says it takes three months or more of daily use, that the effect reverses within 12 months of stopping, and that 3.8% of men on it reported a sexual side effect in the first year, against 2.1% on placebo, and these cleared in men who stopped and in most who kept taking it15.
Whether to start, stop or combine either drug is a decision for the prescriber, who can also say whether a peptide serum fits alongside it. A PubMed search on November 20, 2026 found no trial of a peptide added to finasteride.
How do you judge a peptide hair product?
- Find the peptide on the ingredient list, and check whether a study tested that peptide or a blend that also holds caffeine, biotin or plant extracts.
- Check who the study was in: people, mice or cells, and scalp or eyebrows.
- Before the first use, photograph the top of your head and your parting in the same light and angle, hair dry and combed the same way.
- Write down the start date, the product and its strength.
- Use it the same way every day, and compare new photos with the first set at month 4; the peptide trials above read their results at 4 to 6 months235.
- If your hair loss is sudden or comes in patches, see a doctor or dermatologist before trying any product, since the minoxidil label rules those cases out of self-treatment14.
Commonly reported: peptide serums feel like a light lotion and rarely irritate; users describe less shedding first and new fine hairs later, from about month three if at all. Copper serums can leave a faint blue tint.
- Keep the same photo set and the same start date, so month four is compared with day one, not with memory.
PepVault's side-effects log keeps each entry with its date, a severity from 1 to 5 and a note, so an itchy week sits beside your start date. Log it in PepVault
A face check-in in PepVault's Body tab saves a dated photo with your note, and Compare puts any two check-ins side by side. Track your weight in PepVault
Sources
- Joerg L, Zafar K, Jagdeo J. Peptides for hair growth and treatment of hair loss and alopecia: a systematic review. J Drugs Dermatol. 2026;25(11):1026-1032. PubMed 42976838
- Iwabuchi T et al. The topical penta-peptide Gly-Pro-Ile-Gly-Ser increases the proportion of thick hair in Japanese men with androgenetic alopecia. J Cosmet Dermatol. 2016. PubMed 27030543
- Lueangarun S, Panchaprateep R. An herbal extract combination (biochanin A, acetyl tetrapeptide-3, and ginseng extracts) versus 3% minoxidil solution for the treatment of androgenetic alopecia: a 24-week, prospective, randomized, triple-blind, controlled trial. J Clin Aesthet Dermatol. 2020. PubMed 33584955
- Bikash C. Topical alternatives for hair loss: beyond the conventional. Int J Trichol. 2025. PubMed 40654553
- Lee WJ et al. Efficacy of a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide on hair growth. Ann Dermatol. 2016. PubMed 27489425
- Bo SL et al. The efficacy of 2% copper peptide (GHK-Cu) serum for eyebrow hypotrichosis: a randomized, double-blind, vehicle-controlled, split-face comparative study. Procedia of Multidisciplinary Research. 2026;4(5). so09.tci-thaijo.org
- Pyo HK et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. PubMed 17703734
- Philp D et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004. PubMed 14657002
- Gao X et al. Thymosin beta-4 induces mouse hair growth. PLoS One. 2015. PubMed 26083021
- Lee SH et al. Targeting of CXXC5 by a competing peptide stimulates hair regrowth and wound-induced hair neogenesis. J Invest Dermatol. 2017. PubMed 28595998
- Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth: safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018. PubMed 29482481
- Olsen EA et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002. PubMed 12196747
- Kaufman KD et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998. PubMed 9777765
- DailyMed. Men's Rogaine Extra Strength (minoxidil 5%) topical solution, drug facts label (Kenvue). dailymed.nlm.nih.gov
- DailyMed. Propecia (finasteride) 1 mg tablets, prescribing information (Organon, Oct 2024). dailymed.nlm.nih.gov
- Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. PubMed 22962027
- Ryu YC et al. CXXC5 mediates DHT-induced androgenetic alopecia via PGD2. Cells. 2023 (conflict-of-interest statement). PubMed 36831222
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.